Literature DB >> 29742660

Management of Labor and Delivery After Fetoscopic Repair of an Open Neural Tube Defect.

Jaden R Kohn1, Vibha Rao, Allison A Sellner, Dina Sharhan, Jimmy Espinoza, Alireza A Shamshirsaz, William E Whitehead, Michael A Belfort, Magdalena Sanz Cortes.   

Abstract

OBJECTIVE: To report labor, delivery, and neonatal outcomes in a cohort of women delivering neonates who had undergone fetoscopic neural tube defect repair.
METHODS: We conducted a retrospective cohort study from April 2014 to January 2018. All patients met Management of Myelomeningocele Study eligibility criteria. We included patients with completed second-trimester fetoscopic neural tube defect repair (laparotomy, uterine exteriorization, and minimally invasive access through two or three uterine ports) followed by standardized management of labor and delivery at our institution. Outcomes included rates of vaginal delivery, term delivery, and intrapartum cesarean delivery as well as obstetric and neonatal outcomes after oxytocin. Complications of interest included preterm prelabor rupture of membranes, chorioamnionitis, uterine dehiscence or rupture, 5-minute Apgar score less than 7, and neonatal acidosis (umbilical artery pH less than 7.15).
RESULTS: Thirty-four patients had fetoscopic repair, followed by 17 vaginal deliveries (50%, 95% CI 32-68%). Median gestational age was 38 1/7 weeks at vaginal delivery (range 26 0/7-40 2/7 weeks of gestation) and 37 1/7 weeks of gestation at cesarean delivery (range 25 5/7-40 5/7 weeks of gestation); 62% of deliveries occurred at term. Eight patients had prelabor cesarean delivery: three nonurgent and five urgent (for nonreassuring fetal heart tracings). Twenty-six patients labored; six were induced and 20 labored spontaneously. Of the latter, five were augmented. Of 26 laboring patients, 17 delivered vaginally and nine underwent urgent cesarean delivery (35%, 95% CI 17-56%; seven nonreassuring fetal heart tracings and two breech). There were no cases of uterine rupture or dehiscence. Most (94%, 95% CI 80-99%) had normal 5-minute Apgar scores; one neonate (3%, 95% CI 0-15%) had acidosis but normal Apgar scores.
CONCLUSION: Our data regarding trial of labor, use of low-dose oxytocin, and vaginal delivery after prenatal fetoscopic neural tube defect repair are reassuring. Importantly, fetoscopic repair may permit delivery at advanced gestational ages.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29742660     DOI: 10.1097/AOG.0000000000002577

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Subsequent pregnancy outcomes after open maternal-fetal surgery for myelomeningocele.

Authors:  William H Goodnight; Ozan Bahtiyar; Kelly A Bennett; Stephen P Emery; J B Lillegard; Allan Fisher; Ruth Goldstein; Jillian Jatres; Foong-Yen Lim; Laurence McCullough; Ueli Moehrlen; Julie S Moldenhauer; Anita J Moon-Grady; Rodrigo Ruano; Daniel W Skupski; Elizabeth Thom; Marjorie C Treadwell; KuoJen Tsao; Amy J Wagner; Lindsay N Waqar; Michael Zaretsky
Journal:  Am J Obstet Gynecol       Date:  2019-03-15       Impact factor: 8.661

2.  Influence of painless delivery on the maternal and neonatal outcomes under the guidance of new concept of labor.

Authors:  Xing Li; Cailiang Wu; Xuexin Zhou; Jin Zhang; Huifang Lu; Shuying Chen; Xianming Xu; Hao Wu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

3.  Maternal complications following open and fetoscopic fetal surgery: A systematic review and meta-analysis.

Authors:  Adalina Sacco; Lennart Van der Veeken; Emma Bagshaw; Catherine Ferguson; Tim Van Mieghem; Anna L David; Jan Deprest
Journal:  Prenat Diagn       Date:  2019-02-27       Impact factor: 3.050

4.  Fetoscopic myelomeningocoele closure: Is the scientific evidence enough to challenge the gold standard for prenatal surgery?

Authors:  E Joanne Verweij; Martine C de Vries; Esther J Oldekamp; Alex J Eggink; Dick Oepkes; Femke Slaghekke; Jochem K H Spoor; Jan A Deprest; Jena L Miller; Ahmet A Baschat; Philip L J DeKoninck
Journal:  Prenat Diagn       Date:  2021-04-05       Impact factor: 3.050

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.